The Sympathetic Nervous System Alterations in Human Hypertension

Circulation Research

Volumn 116, Issue 6, 2015, Pages 976-990

  Grassi, Guido ^a,b   Mark, Allyn ^c   Esler, Murray ^d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF IOWA   (United States)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

hypertension essential; renal insufficiency; sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; INSULIN; LEPTIN; MELANOCORTIN; NORADRENALIN; ANTIHYPERTENSIVE AGENT;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; CARDIOVASCULAR FUNCTION; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EFFERENT NERVE; END STAGE RENAL DISEASE; ESSENTIAL HYPERTENSION; HEART RATE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY DENERVATION; KIDNEY DISEASE; KIDNEY NERVE; METABOLIC SYNDROME X; MICRONEUROGRAPHY; MUSCLE SYMPATHETIC NERVE ACTIVITY; NERVE CONDUCTION; NEUROGRAPHY; NEUROIMAGING; NONHUMAN; NORADRENALIN BLOOD LEVEL; OBESITY; PRESSORECEPTOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; REVIEW; SENSORY NERVE; SUBCUTANEOUS FAT; SYMPATHECTOMY; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; SYMPATHETIC TONE; ANIMAL; BLOOD; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL TRIAL (TOPIC); COMPLICATION; DEFICIENCY; FORECASTING; HYPERINSULINISM; HYPERTENSION, RENAL; INNERVATION; INSULIN RESISTANCE; KIDNEY; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SYMPATHETIC NERVE CELL; VASOCONSTRICTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; FORECASTING; HEART RATE; HUMANS; HYPERINSULINISM; HYPERTENSION; HYPERTENSION, RENAL; INSULIN RESISTANCE; KIDNEY; KIDNEY DISEASES; LEPTIN; MELANOCORTINS; METABOLIC SYNDROME X; MULTICENTER STUDIES AS TOPIC; NEUROIMAGING; NOREPINEPHRINE; OBESITY; SYMPATHECTOMY; SYMPATHETIC FIBERS, POSTGANGLIONIC; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION;

EID: 84938336300     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.303604     Document Type: Review

References (125)

1. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014;114:1004-1021. doi: 10.1161/ CIRCRESAHA.113.302549.
2. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913-919.
3. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560-563.
4. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897-1904. doi: 10.1172/JCI118235.
5. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097-3101. doi: 10.1161/01. CIR.0000103123.66264.FE.
6. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-1365. doi: 10.1007/s00125-005-1798-z.
7. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823. doi: 10.1056/NEJM198409273111303.
8. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001; 22:1136-1143.
9. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001;57:833-838.
10. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
11. Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, Roveda F, de Matos LN, Braga AM, Middlekauff HR, Negrão CE. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol. 2009;135:302-307. doi: 10.1016/j.ijcard.2008.03.056.
12. Andreas S, Haarmann H, Klarner S, Hasenfuss G, Raupach T. Increased sympathetic nerve activity in COPD is associated with morbidity and mortality. Lung. 2014;192:235-241. doi: 10.1007/s00408-013-9544-7.
13. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22:208-215.
14. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto- control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-1490. doi: 10.1161/HYPERTENSIONAHA.112.201186.
15. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A. Renal sympathetic denervation in patients with treatmentresistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526-532. doi: 10.1161/HYPERTENSIONAHA.113.01452.
16. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatmentresistant hypertension. Hypertension. 2014;63:991-999. doi: 10.1161/ HYPERTENSIONAHA.114.03246.
17. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Roche- Singh K, Bakris GL; the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370:1393-1340.
18. Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-2045. doi: 10.1016/j.jacc.2013.08.1616.
19. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic- nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934. doi: 10.1056/NEJMc0904179.
20. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281. doi: 10.1016/S0140-6736(09)60566-3.
21. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-464. doi: 10.1161/ HYPERTENSIONAHA.111.00194.
22. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-734.
23. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635-1639.
24. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del Bo A, Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994;90:248-253.
25. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252. doi: 10.1172/JCI115260.
26. Eckberg DL. Sympathovagal balance: a critical appraisal. Circulation. 1997;96:3224-3232.
27. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70:963-985.
28. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3-20.
29. Meredith IT, Eisenhofer G, Lambert GW, Jennings GL, Thompson J, Esler MD. Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure. Hypertension. 1992;19:628-633.
30. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423-3429.
31. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:77-84.
32. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1988; 14:1277-1283.
33. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens. 1993;11:647-655.
34. Rea RF, Hamdan M. Baroreflex control of muscle sympathetic nerve activity in borderline hypertension. Circulation. 1990;82:856-862.
35. Schobel HP, Heusser K, Schmieder RE, Veelken R, Fischer T, Luft FC. Evidence against elevated sympathetic vasoconstrictor activity in borderline hypertension. J Am Soc Nephrol. 1998;9:1581-1587.
36. Levy RL, White PD, Stroud WD, Hillman CC. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA. 1945;129:585-588.
37. Gudmundsdottir H, Strand AH, Høieggen A, Reims HM, Westheim AS, Eide IK, Kjeldsen SE, Os I. Do screening blood pressure and plasma catecholamines predict development of hypertension? Twenty-year follow-up of middle-aged men. Blood Press. 2008;17:94-103. doi: 10.1080/08037050801972923.
38. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72.
39. Grassi G, Seravalle G, Bertinieri G, Turri C, Dell'Oro R, Stella ML, Mancia G. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens. 2000;18:587-593.
40. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711-1717.
41. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol. 2002;40:126-132.
42. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565. doi: 10.1161/01. CIR.0000081775.72651.B6.
43. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217-222. doi: 10.1016/j.amjhyper.2003.10.010.
44. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999-2005. doi: 10.1161/ CIRCULATIONAHA.106.668863.
45. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Spaziani D, Mancia G. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205-209. doi: 10.1161/HYPERTENSIONAHA.108.121467.
46. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804-1814. doi: 10.1161/CIRCRESAHA.114.302524.
47. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A. 1989;11(suppl 1):75-89.
48. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918. doi: 10.1056/NEJM199212313272704.
49. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-1979.
50. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239-3244.
51. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846-851. doi: 10.1161/HYPERTENSIONAHA.110.164780.
52. Folkow B. The Fourth Volhard Lecture: cardiovascular structural adaptation: its role in the initiation and maintenance of primary hypertension. Clin Sci. 1978;4(suppl 3): 3S-22S
53. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
54. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057-1062.
55. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G, Friberg P. Increased sympathetic nerve activity in renovascular hypertension. Circulation. 1999;99:2537-2542.
56. Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95:4756-4761. doi: 10.1210/jc.2010-0823.
57. Grassi G. Colombo M, Seravalle G, Spaziani G, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity and congestive heart failure. Hypertension. 1998;31:84-87.
58. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538-542.
59. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-La Rocca HP, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125-1133.
60. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48:787-796. doi: 10.1161/01. HYP.0000242642.42177.49.
61. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61:1081-1090.
62. Bray GA. Obesity, a disorder of nutrient partitioning: the MONA LISA hypothesis. J Nutr. 1991;121:1146-1162.
63. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634-2640.
64. Spraul M, Ravussin E, Fontvieille AM, Rising R, Larson DE, Anderson EA. Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. J Clin Invest. 1993;92:1730-1735. doi: 10.1172/JCI116760.
65. Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension. 2000;36:531-537.
66. Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E, Lambert G. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50:862-868. doi: 10.1161/HYPERTENSIONAHA.107.094649.
67. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14:694-698.
68. Shibao C, Gamboa A, Diedrich A, Ertl AC, Chen KY, Byrne DW, Farley G, Paranjape SY, Davis SN, Biaggioni I. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49:27-33. doi: 10.1161/01.HYP.0000251679.87348.05.
69. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5998-6005. doi: 10.1210/jc.2005-0961.
70. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533-2536.
71. Alvarez GE, Ballard TP, Beske SD, Davy KP. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol. 2004;287:H414-H418. doi: 10.1152/ajpheart.01046.2003.
72. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44:847-852. doi: 10.1161/01. HYP.0000147893.08533.d8.
73. Rahmouni K. Obesity-associated hypertension: recent progress in deciphering the pathogenesis. Hypertension. 2014;64:215-221. doi: 10.1161/ HYPERTENSIONAHA.114.00920.
74. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271-17276. doi: 10.1074/jbc.R110.113175.
75. Lim K, Burke SL, Head GA. Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits. Hypertension. 2013;61:628-634. doi: 10.1161/HYPERTENSIONAHA.111.00705.
76. Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305:R566-R581. doi: 10.1152/ ajpregu.00180.2013.
77. Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG. State-of-theart- lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension. 1999;33:537-541.
78. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia. 1992;35:873-879.
79. Vollenweider P, Randin D, Tappy L, Jéquier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest. 1994;93:2365-2371. doi: 10.1172/JCI117242.
80. Brands MW, Mizelle HL, Gaillard CA, Hildebrandt DA, Hall JE. The hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am J Hypertens. 1991;4:164-168.
81. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension. 1993;21:136-141.
82. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990;85:1844-1852. doi: 10.1172/JCI114644.
83. Lembo G, Napoli R, Capaldo B, Rendina V, Iaccarino G, Volpe M, Trimarco B, Saccà L. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest. 1992;90:24-29. doi: 10.1172/JCI115842.
84. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21:618-623.
85. Lembo G, Capaldo B, Rendina V, Iaccarino G, Napoli R, Guida R, Trimarco B, Saccá L. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol. 1994;266:E242-E247.
86. Gamboa A, Okamoto LE, Arnold AC, Figueroa RA, Diedrich A, Raj SR, Paranjape SY, Farley G, Abumrad N, Biaggioni I. Autonomic blockade improves insulin sensitivity in obese subjects. Hypertension. 2014;64:867-874. doi: 10.1161/HYPERTENSIONAHA.114.03738.
87. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. J Hypertens. 1994;12:495-502.
88. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360:44-52. doi: 10.1056/ NEJMoa0803085.
89. Sayk F, Heutling D, Dodt C, Iwen KA, Wellhoner JP, Scherag S, Hinney A, Hebebrand J, Lehnert H. Sympathetic function in human carriers of melanocortin-4 receptor gene mutations. J Clin Endocrinol Metab. 2010;95:1998-2002. doi: 10.1210/jc.2009-2297.
90. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptormediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100:270-278. doi: 10.1172/JCI119532.
91. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999;84:3686-3695. doi: 10.1210/jcem.84.10.5999.
92. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab. 2013;98:E491-E496. doi: 10.1210/jc.2012-3009.
93. DiBona GF. The functions of the renal nerves. Rev Physiol Biochem Pharmacol. 1982;94:75-181.
94. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.
95. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245-R253. doi: 10.1152/ajpregu.00647.2009.
96. Esler M, Lambert E, Schlaich M. Point:Counterpoint. Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol. 2010;109;1996-1998.
97. Roman RJ, Cowley AW Jr. Characterization of a new model for the study of pressure-natriuresis in the rat. Am J Physiol. 1985;248:F190-F198.
98. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26:861-865.
99. Brecht HM, Ernst W, Koch KM. Plasma noradrenaline levels in regular haemodialysis patients. Proc Eur Dial Transplant Assoc. 1976;12:281-290.
100. McGrath BP, Ledingham JG, Benedict CR. Catecholamines in peripheral venous plasma in patients on chronic haemodialysis. Clin Sci Mol Med. 1978;55:89-96.
101. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-939. doi: 10.1681/ASN.2008040402.
102. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878-882.
103. Adamczak M, Zeier M, Dikow R, Ritz E. Kidney and hypertension. Kidney Int. 2002;61(suppl) :S62-S67.
104. Strojek K, Grzeszczak W, Górska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12:602-605.
105. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-1717. doi: 10.1097/01.hjh.0000084733.53355.c3.
106. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257. doi: 10.1681/ASN.2011111062.
107. Schlaich MP, Bart B, Hering D, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiology. 2013;168:2214-2220
108. Zimmer K. Soul Made Flesh. London: The Random House (Arrow Books); 2004:188-207.
109. Hamilton WF, Richards DW. Output of the heart. In: Fishman AP and Richards DW, eds. Circulation of the Blood. Men and Ideas. Bethesda, MD: American Physiological Society;1982:87-90.
110. Julius S, Esler M, eds. The Nervous System in Arterial Hypertension, Springfield, IL: Charles C. Thomas; 1976.
111. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1, 266 cases. J Am Med Assoc. 1953;152:1501-1504.
112. Paton WDM, Zaimis EJ. Paralysis of autonomic ganglia by methonium salts. Brit J Pharmacol. 1951;6;155-168.
113. van Zwieten PA. Development of antihypertensive drugs: from the bench to the clinic. In: Birkenhager WH, Robertson JIS, Zanchetti A, eds. Handbook of Hypertension, Hypertension in the Twentieth Century: Concepts and Achievements. Amsterdam: Elsevier; 2004:457-486.
114. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
115. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
116. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, De Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:765-773.
117. Symplicity HTN-2 Investigators. Renal sympathetic denervationin patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-1309.
118. Brest AN, Wiener L, Bachrach B. Bilateral carotid sinus nerve stimulation in the treatment of hypertension. Am J Cardiol. 1972;29:821-825.
119. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Kolodgie F, Joner M, Virmani R. Anatomical distribution of human renal sympathetic nerves: pathological study. J Am Coll Cardiol. 2014; 64:635-43.
120. Oldham JB. Denervation of the kidney. Hunterian Lecture of the Royal College of Surgeons, England. 9th March, 1950. Ann R Coll Surg Engl. 1950;7:222-245.
121. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132-2140. doi: 10.1093/ eurheartj/eht197.
122. Mabin T, Sapoval M, Cabane V, Stemmet J. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2013;8:57-61.
123. Meredith IT, Esler MD, Cox HS, Lambert GW, Jennings GL, Eisenhofer G. Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clin Auton Res. 1991;1:187-194.
124. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha- Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. doi: 10.1056/NEJMoa1402670.
125. Shun-Shin MJ, Howard JP, Francis DP. Removing the hype from hypertension. BMJ. 2014;348:g1937.